In recent years, researchers have realized that many products, including pharmaceuticals, have ended up where they’re not supposed to be — in our drinking water. But now scientists have developed a way to make drugs that break down into harmless compounds before they contaminate our taps. Their report appears in ACS’ journal Environmental Science & Technology.
A wide range of active ingredients originating from pesticides, shampoos, lotions, cosmetics, disinfectants and drugs get washed into sewage systems or rivers and streams, ending up in our tap water. Scientists don’t have a complete picture yet of what effects these substances have on wildlife and human health, but they are a major concern. Researchers have detected them in low levels in streams and rivers across the United States and in other countries. To address the specific problem of medications in the environment, Klaus Kümmerer and colleagues made tweaks to pharmaceuticals so they degrade after they’ve passed through both the body and sewage treatment systems, which aren’t capable of scrubbing wastewater of all contaminants.
The researchers chose to work with a commonly used drug called propranolol — a beta blocker prescribed to treat high blood pressure and to prevent heart problems. It is very stable and has been found in sewage. They made a small molecular change in its structure that didn’t affect its beta blocking activity but allowed it to break down more easily than the original form. Further studies are needed, but initial testing showed that the altered drug and its byproducts are likely not toxic. The researchers suggest that a similar approach could be used to re-design other classes of drugs and chemicals to make them more environmentally friendly, too.
The Latest on: Pharmaceuticals that degrade
[google_news title=”” keyword=”Pharmaceuticals that degrade” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmaceuticals that degrade
- Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Chargeon May 18, 2024 at 1:10 am
Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, ...
- More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024on May 17, 2024 at 1:23 pm
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition. ...
- Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peerson May 16, 2024 at 10:25 am
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, maker of the weight loss drug Wegovy, is tops, according to a new analysis. #STATBreakthrough ...
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlightson May 15, 2024 at 5:30 am
Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a ...
- Cutting-edge insulin is good. But it’s the ‘trailing edge’ of older versions that can keep it affordableon May 15, 2024 at 1:29 am
Giving people access to the trailing edge — older but effective products that manufacturers discontinue — offers them more-affordable options.
- 2 Top Pharma Stocks That Just Keep Getting Better and Betteron May 14, 2024 at 6:53 am
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
- Zantac pharma exec calls heartburn drug safe and effective during testimony against cancer claimson May 13, 2024 at 5:41 pm
The executive, a medical doctor who oversaw drug safety for decades at drugmaker GSK, repeatedly pushed back on the claim that the popular heartburn drug causes cancer.
- Derivatives of the thalidomide compound drive resistant cancer cells to their deathson May 13, 2024 at 8:15 am
A study by Goethe University Frankfurt points to the possibility that thalidomide derivatives are potentially suitable for treating cancer. Thalidomide was marketed in the 1950s as a sleeping pill. It ...
- Hebrew University study finds zebrafish provides clues to RNA's role in embryo formationon May 11, 2024 at 6:11 pm
A new study at the Hebrew University in Jerusalem (HU) presents insights into mRNA regulation during embryonic development in zebrafish.
- Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costlyon May 10, 2024 at 4:06 pm
In a Friday interview with CNBC’s Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson explained how his company uses new AI technology to develop drugs.
via Bing News